Hongkang Zhang
Senior Director - Pain Therapeutic Lead Quiver Bioscience
In his role as Senior Director, Pain Therapeutics Lead at Quiver Bioscience, Hongkang Zhang manages a team of scientists and researchers to develop non-opioid therapeutics, including small molecules and antisense oligonucleotides, for chronic pain treatment. He has over 15 years of experience in leading research projects in the academic and biotech industry sectors, studying channelopathy related disorders including pain, epilepsy and cardiac arrhythmias. Hongkang received a B.S. in Biology from Peking University and a Ph.D. in Neuroscience from Johns Hopkins University. He finished his postdoctoral training in the Chemistry Department of Harvard University.
Seminars
Wednesday 28th January 2026
NaV1.7 Targeting Antisense Oligonucleotides: Emerging Modalities for Pain & Pipeline Development
1:00 pm
- Utilizing ASOs as a novel way to modulate NaV1.7, which can circumvent the existing issues with small molecule inhibitors (e.g. autonomic side effects)
- Exploring how Quiver’s integrated platform based on all-optical electrophysiology and machine learning has led to identifying novel candidate molecules alongside therapeutic targets
- Demonstrating how Quiver’s platform can enrich the genetic medicine drug candidates with maximized therapeutic index
New Data
Thursday 29th January 2026
Fireside Chat: Setting The New Gold Standard: Human-Centric Pain Models Using DRG Neurons, Tissue Models & IPSCs
11:30 am
- Discuss the technological, regulatory, and organizational shifts required to embed human-centric pain models as the new industry standard
- What are the current barriers to adoption? How can biopharma, CROs, and regulators collaborate to accelerate validation and scale-up of these models across the pipeline
